ABSTRACT
OBJECTIVES: Hepatitis C is the leading cause of chronic hepatitis in the United States. Little information is available regarding how persons with hepatitis C view health with their disease. We studied patients' perceptions about the value of hepatitis C health states and evaluated whether physicians understand their patients' perspectives about this disease. METHODS: A total of 50 consecutive persons with hepatitis C were surveyed when they presented as new patients to a hepatology practice. Subjects provided utility assessments (preference values) for five hepatitis C health states and for treatment side effects. They also stated their threshold for accepting antiviral therapy. Five hepatologists used the same scales to estimate their patients' responses. RESULTS: On average, patients believed that hepatitis C without symptoms was associated with an 11% reduction in preference value from that of life without infection, and the most serious condition (severe symptoms, cirrhosis) was believed to carry a 73% decrement. Patients judged the side effects of antiviral therapy quite unfavorably, and their median stated threshold for accepting treatment was a cure rate of 80%. Physicians' estimates were not significantly associated with patients' preference values for hepatitis C health states, treatment side effects, or with patients' thresholds for accepting treatment. In multivariate analysis, patients' stated thresholds for taking treatment were significantly associated with their decisions regarding therapy (beta = -2.72+/-1.21, p = 0.025). CONCLUSIONS: There was little agreement between patients' preference values about hepatitis C and their physicians' estimates of those values. Utility analysis could facilitate shared decision making about hepatitis C.
Subject(s)
Health Status , Hepatitis C/psychology , Patient Satisfaction , Physicians , Adult , Female , Hepatitis C/drug therapy , Humans , Male , Middle Aged , Severity of Illness IndexABSTRACT
We have previously shown that human metallopanstimulin-1 (MPS-1) is a ubiquitous 9.4-kd multifunctional ribosomal S27/nuclear "zinc finger" protein that is expressed at high levels in a wide variety of actively proliferating cells and tumor tissues. In this study, we examined the expression of MPS-1 in chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Tissue samples were obtained at the time of tumor resection, needle biopsy, or liver transplantation. MPS- 1 was studied by immunohistochemistry by use of specific antibodies to the N-terminus of MPS-1 in a biotin/streptavidin-amplified system. In chronic hepatitis, hepatocytes had very weak MPS-1 immunostaining. In contrast, hepatocytes in regenerating cirrhotic nodules stained strongly for MPS-1. In well-differentiated hepatocellular carcinoma, MPS-1 presence was intense at the periphery of the malignant nodule. In poorly differentiated hepatocellular carcinoma, MPS-1 presence was notably intense in malignant hepatocytes invading the septal tissues, in close contact with neovascular structures. These results suggest that MPS-1 may be involved in both progression toward malignancy in regenerating cirrhotic nodules and in subsequent steps of hepatocarcinogenesis.
Subject(s)
Carcinoma, Hepatocellular/genetics , Cell Transformation, Neoplastic , Gene Expression Regulation, Neoplastic , Hepatitis, Chronic/genetics , Liver Cirrhosis/genetics , Liver Neoplasms/genetics , Metalloproteins/biosynthesis , Nuclear Proteins/biosynthesis , Ribosomal Proteins/biosynthesis , Antibodies/analysis , Carcinoma, Hepatocellular/pathology , Cell Differentiation , Disease Progression , Hepatitis, Chronic/pathology , Hepatocytes/immunology , Hepatocytes/physiology , Humans , Immunohistochemistry , Liver Cirrhosis/pathology , Liver Neoplasms/pathology , Liver Regeneration/genetics , Liver Regeneration/physiology , RNA-Binding ProteinsABSTRACT
BACKGROUND: Hepatitis C virus infection persists after liver transplantation and causes recurrent liver injury in the majority of patients. Standard dose interferon therapy has been largely unsuccessful for hepatitis C in transplant recipients. METHODS: Twelve patients, at least 7 months posttransplant, with detectable hepatitis C virus RNA in serum and features of hepatitis C on liver biopsy were randomized to interferon-alpha2a, 3 mU daily for 12 months (n=8) or no treatment (n=4). The tolerability of daily interferon dosing in liver transplant recipients was evaluated and effects on hepatitis C virus RNA level, quasispecies evolution, and liver histology were studied. RESULTS: Treated patients had an improvement in histological activity index at the end of therapy relative to controls (median reduction of 2 versus median increase of 1.5) (P=0.04). Four treated patients had a virological response (all bDNA negative, one qualitative polymerase chain reaction negative) compared with none of the untreated patients. Only two of six treated patients tested had evidence of quasispecies diversification on therapy. Seven of eight patients in the treatment group required dose reduction for fatigue and/or depression. They tolerated 1.5 mU of interferon-alpha2a daily. Two treated patients developed graft dysfunction, one of who had histological evidence of rejection and subsequent graft loss. CONCLUSIONS: Low daily doses of interferon were tolerated by liver transplant recipients and provided histological benefit without associated quasispecies diversification in most cases. These findings provide a rationale to study low dose daily or pegylated interferon maintenance therapy for the management of hepatitis C posttransplant.
Subject(s)
Hepatitis C/drug therapy , Interferon-alpha/therapeutic use , Liver Transplantation , Adult , Aged , Fatigue/chemically induced , Female , Genetic Variation , Hepacivirus/genetics , Humans , Interferon alpha-2 , Interferon-alpha/administration & dosage , Interferon-alpha/adverse effects , Liver/pathology , Male , Middle Aged , Nausea/chemically induced , RNA, Viral/blood , Recombinant Proteins , Species Specificity , Time FactorsABSTRACT
Cytokine production has been implicated in the antiviral response to interferon-alpha (IFN-alpha) in hepatitis C and in the development of IFN-alpha-related side effects. We characterized acute changes in serum cytokine levels following administration of a single dose of consensus IFN (IFN-con1) and during continuous treatment of chronic hepatitis C patients. Serum samples were collected at baseline, at multiple times early after IFN administration, and weekly thereafter. Viral RNA titers were assessed by RT-PCR, and viral kinetics were followed. ELISA assays were used to measure IFN-gamma, tumor necrosis factor-alpha (TNF-alpha), interleukin-2 (IL-2), IL-4, IL-6, and IL-16. Serum cytokine levels were low at baseline. IL-6 was detected in patients with hepatitis C but not in healthy control subjects by either ELISA or RT-PCR, indicating that low levels of circulating IL-6 were associated with hepatitis C infection. None of the cytokines measured increased significantly after IFN administration except for IL-6. IL-6 levels rose rapidly, peaked at 6-15 h in a dose-dependent manner, and returned to baseline by 48 h in both patients receiving a single dose of IFN and those receiving continuous treatment. This was confirmed by RT-PCR. Pretreatment IL-6 levels were directly correlated with area under the curve (AUC) for IL-6 during the 24 h after IFN dosing (r = 0.611, p = 0.007). Viral titers decreased within 24-48 h after a single dose of IFN-con1. Changes in hepatitis C RNA titers were not significantly associated with pretreatment IL-6 levels or with changes in IL-6 levels. In conclusion, (1) baseline serum cytokine levels, except for IL-6, were low or within the normal range in patients with hepatitis C, (2) IL-6 levels were detected in some patients with hepatitis C before treatment but not in healthy controls, (3) IL-6 levels increased acutely after a single dose of IFN-alpha, and IL-6 induction was related to baseline IL-6 level, and (4) changes in IL-6 levels did not correlate with the early virologic response to IFN.
Subject(s)
Antiviral Agents/therapeutic use , Hepatitis C/drug therapy , Hepatitis C/immunology , Interferon Type I/therapeutic use , Interleukin-6/blood , Cytokines/blood , Hepacivirus/genetics , Hepacivirus/isolation & purification , Hepatitis C/virology , Humans , Interferon-alpha , Interleukin-6/genetics , Kinetics , Middle Aged , RNA, Messenger/biosynthesis , RNA, Viral/analysis , Recombinant ProteinsABSTRACT
OBJECTIVE: The aim of this study was to evaluate the role of transjugular intrahepatic portosystemic shunt (TIPS) in patients who present with portal vein thrombosis (PVT) or Budd-Chiari Syndrome (BCS). METHODS: Nine patients with recent PVT and four patients with BCS underwent TIPS. The diagnosis was confirmed by color Doppler ultrasound and by angiogram in most patients. Patients were followed clinically and had TIPS checked periodically for patency. The end point was mortality, subsequent surgical shunting or orthotopic liver transplantation (OLT). RESULTS: TIPS was placed in 13 of 15 (87%) patients with BCS or PVT. The mean decrease in pressure gradient was 56%. Median and mean follow-up were 14 months and 16.9 months. Procedure related complications occurred in two of 13 (15%), both in the PVT group. Direct procedural mortality was one of 13 (8%). The majority of patients with PVT (five of eight) underwent OLT. Of the remaining three, one patient subsequently developed a cavernous transformation of portal vein but is stable, one patient is stable, without further variceal bleeding, and one patient died because of multiple organ failure. In patients with BCS, three of four (75%) did well with TIPS, but one patient required immediate surgical shunting after occlusion of the TIPS. Two patients underwent OLT and the fourth patient is stable 2 yr later but has cirrhosis on biopsy. CONCLUSIONS: In patients with BCS, TIPS placement is effective and can be used as a bridge to liver transplantation. TIPS in the noncavernous PVT group should only be recommended when cirrhosis and uncontrollable variceal bleeding are present.
Subject(s)
Budd-Chiari Syndrome/surgery , Portal Vein , Portasystemic Shunt, Transjugular Intrahepatic , Venous Thrombosis/surgery , Adult , Aged , Female , Follow-Up Studies , Humans , Liver Transplantation , Male , Middle Aged , Portasystemic Shunt, Transjugular Intrahepatic/adverse effects , Reoperation , Treatment OutcomeABSTRACT
A patient presented with pruritus and recent elevation of aminotransferases. The case fulfilled most of the criteria for the diagnosis of autoimmune hepatitis and achieved clinical and complete biochemical response to steroid therapy. However, the liver biopsy specimen revealed an unusual histological pattern consisting of severe centrilobular necrosis demarcated by a thin rim of hepatitic reaction. In contrast, the portal tracts appeared almost normal. This histological appearance has not been associated with autoimmune hepatitis. This presentation and the histology may represent an early pattern of autoimmune injury to the liver.
Subject(s)
Autoimmune Diseases/pathology , Hepatitis/pathology , Liver/pathology , Adult , Anti-Inflammatory Agents/therapeutic use , Autoimmune Diseases/drug therapy , Azathioprine/therapeutic use , Chronic Disease , Drug Therapy, Combination , Female , Hepatitis/drug therapy , Hepatitis/immunology , Humans , Immunosuppressive Agents/therapeutic use , Liver/immunology , Methylprednisolone/therapeutic use , NecrosisABSTRACT
BACKGROUND: Human metallopanstimulin (MPS-1) is a 9.4-kDa multifunctional ribosomal S27 nuclear "zinc finger" protein which is expressed in a wide variety of actively proliferating cells and tumor tissues. In this paper, we present a case of overexpression of MPS-1 in colon cancer tissues of a seventeen year old male. METHODS: Biopsies at the anastomosis and adjacent normal colonic mucosa were obtained by colonoscopy twelve months after right hemicolectomy for an ascending colon well differentiated adenocarcinoma. Immunohistochemical localization of MPS-1 protein was performed by using specific anti-MPS-1 antibodies directed against the N-terminal region of this protein. RESULTS: Immunohistochemistry demostrated an overexpression of MPS-1 in colonic mucosa crypts in the samples obtained at the anastomosis. In contrast, no expression of MPS-1 was observed in the adjacent normal mucosa. Histopathology performed with hematoxilin and eosin staining revealed focal crypt distortion and proliferation, but no carcinoma. CONCLUSIONS: In this case, the overexpression of MPS-1 was a more definitive evidence of malignant transformation than histology, as demonstrated by the clinical course of the disease. The results support the hypothesis that increased levels of tissue MPS-1 may correlate with a more aggressive behavior of colon malignancy.
Subject(s)
Adenocarcinoma/metabolism , Colonic Neoplasms/metabolism , Metalloproteins/biosynthesis , Nuclear Proteins/biosynthesis , Ribosomal Proteins , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Adolescent , Amino Acid Sequence , Biopsy , Colectomy , Colonic Neoplasms/pathology , Colonic Neoplasms/surgery , Colonoscopy , Humans , Immunohistochemistry , Intestinal Mucosa/metabolism , Intestinal Mucosa/pathology , Male , Metalloproteins/analysis , Metalloproteins/chemistry , Molecular Sequence Data , Nuclear Proteins/analysis , Nuclear Proteins/chemistry , Peptide Fragments/chemistry , Peptide Fragments/immunology , RNA-Binding Proteins , Zinc FingersABSTRACT
Hepatocellular carcinoma (HCC) is a common malignancy worldwide. Viral hepatitis B and C and cirrhosis are the most important risk factors. The two most established methods of screening are ultrasound and alpha-fetoprotein serum levels followed serially. The intervals of testing and cost efficacy have not yet been established. When HCC is discovered staging is important in order to guide treatment. Assessment for portal vein patency by ultrasonography and dynamic CT are noninvasive and sensitive. Magnetic resonance imaging and lipiodol CT are also helpful. The treatment depends on the patient's clinical condition related to liver function and other comorbid conditions and the number, size, and location of the lesions. The roles of tumor resection, liver transplantation, percutaneous alcohol injection, transarterial chemoembolization, and systemic chemotherapy are dependent on staging. Careful selection of patients and combined treatment modalities may be the keys to improve survival.
Subject(s)
Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/therapy , Liver Neoplasms/pathology , Liver Neoplasms/therapy , Humans , Neoplasm StagingABSTRACT
BACKGROUND: Transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment of severe portal hypertension complications. Liver transplantation (LT) candidacy has not been a prerequisite to TIPS placement in some medical centers. OBJECTIVES: To investigate the outcome and survival of non-LT candidates after TIPS. METHODS: From November 1991 to February 1994, all patients referred for TIPS placement were evaluated for LT candidacy. Exclusions for LT included: age (> 70 yr), other significant medical conditions, or noncompliance. Indications for TIPS included refractory variceal bleeding during an acute bleed, recurrent bleeding after more than or equal to four sessions of sclerotherapy, or refractory ascites. RESULTS: Sixty patients received TIPS. Nineteen were considered non-LT candidates. Over a 2-yr follow-up, 14 of these non-LT candidates did not survive. Their median age was 63.5 compared with 56.5 yr for LT candidate nonsurvivors (p < 0.05). Among the 14 non-LT candidate nonsurvivors, 10 were Childs C class, and eight had emergent TIPS placement. The 2-year mortality rate was 84% for non-LT candidates versus 24% for LT candidates. Median survival time for non-LT candidates was 2.6 months compared with 20 months in the LT candidates (p < 0.001). Only one death was due to a TIPS-related complication. CONCLUSIONS: TIPS is unquestionably an advancement in the management of patients with portal hypertension complications. Non-LT candidates, compared with LT candidates, tended to be older and of a Child-Pugh C class, and they had survival rates often less than 90 days post-TIPS. Given these high mortality rates, we need to address whether TIPS is indicated in these non-LT candidates.
Subject(s)
Esophageal and Gastric Varices/surgery , Gastrointestinal Hemorrhage/surgery , Hypertension, Portal/surgery , Liver Transplantation , Portasystemic Shunt, Surgical , Esophageal and Gastric Varices/etiology , Esophageal and Gastric Varices/mortality , Female , Follow-Up Studies , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/mortality , Humans , Hypertension, Portal/complications , Hypertension, Portal/mortality , Life Tables , Liver Transplantation/mortality , Male , Middle Aged , Patient Selection , Portasystemic Shunt, Surgical/methods , Portasystemic Shunt, Surgical/mortality , Retrospective Studies , Survival Rate , Time Factors , Treatment OutcomeABSTRACT
The AIDS wasting syndrome (AWS) is characterized by > 10% loss of baseline body weight during 6 months and may occur in patients with or without associated chronic diarrhea. To determine whether the presence of small-intestinal malabsorption is associated with the development of AWS in human immunodeficiency virus (HIV)-infected patients with chronic diarrhea, we retrospectively reviewed the results of D-xylose testing performed in the clinical evaluation of 21 consecutive HIV-infected patients with chronic diarrhea. A thorough search for small-intestinal pathogens was performed including upper endoscopy, duodenal biopsy, and aspirate for culture and ova and parasite examination. These studies were negative in all patients except two who were excluded from the study. In the 19 patients with no identifiable pathogens, the 1-h serum D-xylose concentration was significantly lower in patients with AWS than in those without, 8.3 +/- 0.8 versus 23.7 +/- 3.4 mg/dl, respectively, p < 0.001. Urine D-xylose excretion during 5 h was also significantly lower in the group with AWS, although creatinine clearance was similar in the two groups. Patients with AWS were more often refractory to standard antidiarrheal therapy with loperamide or diphenoxylate and carried a poor prognosis (90% mortality at 1 year versus 22% mortality in the group without AWS). These data indicate that small intestinal malabsorption is a major component in the severe wasting seen in some HIV-infected patients with chronic diarrhea. Patients with markedly abnormal D-xylose tests may require more potent antidiarrheal therapy and are expected to have a high mortality as a possible consequence of intestinal dysfunction.
Subject(s)
Acquired Immunodeficiency Syndrome/complications , Diarrhea/metabolism , HIV Infections/complications , Malabsorption Syndromes/diagnosis , Weight Loss , Xylose/metabolism , Acquired Immunodeficiency Syndrome/metabolism , Chronic Disease , Diarrhea/etiology , HIV Infections/metabolism , Humans , Intestinal Absorption , Malabsorption Syndromes/etiology , Malabsorption Syndromes/metabolism , Male , Retrospective StudiesABSTRACT
The effects of atrial natriuretic factor (ANF) on splanchnic hemodynamics and renal function in portal hypertensive models are described incompletely. Furthermore, ANF-induced vasodilatation and hypotension may limit the assessment of its own renal physiological effects. We infused ANF (human ANF 102-126) to anesthetized portal vein-ligated rats, a model with prehepatic portal hypertension. Arterial pressure was reduced by 17%, but portal pressure was unaffected. Diuresis and natriuresis were explained in part by an increase in glomerular filtration rate; in addition, renal vascular resistance was significantly decreased. The natriuretic response to ANF was slightly, but significantly, decreased in portal hypertensive rats as compared to controls (fractional excretion of sodium, 1.8 +/- 0.4 vs. 2.9 +/- 0.3; P less than .05). The addition of Phe-Ile-Orn-vasopressin, a V1 receptor agonist, normalized arterial pressure but induced a significant decrease in portal pressure (15 +/- 0.9 mm Hg base line vs. 12.8 +/- 0.7 combination group; P less than .01). Furthermore, the combination of both drugs markedly potentiated the natriuretic effects (0.4 +/- 0.1 microEq/min of control vs. 10.0 +/- 2.3 ANF vs. 32.2 +/- 3.3 combination group; P less than .001). The natriuretic potentiation resulted from increments in glomerular filtration rate and renal blood flow. Normalization of arterial pressure may enhance the renal physiological effects of ANF, in this portal hypertensive model.
Subject(s)
Atrial Natriuretic Factor/pharmacology , Hypertension, Portal/physiopathology , Kidney/drug effects , Ornipressin/analogs & derivatives , Splanchnic Circulation/drug effects , Vasopressins , Animals , Drug Synergism , Glomerular Filtration Rate/drug effects , Hemodynamics/drug effects , Male , Natriuresis/drug effects , Ornipressin/pharmacology , Rats , Rats, Inbred StrainsABSTRACT
Brain edema is a major complication of fulminant hepatic failure and is responsible for death in a large percentage of patients. We previously demonstrated the progressive accumulation of water in grey matter areas of the brain in the rabbit with galactosamine-induced fulminant hepatic failure. We now report the electron microscopic morphology of the brain in the same model of acute hepatic failure following the intravenous injection of horseradish peroxidase, an intravascular tracer which forms an electron-dense reaction product. Rabbits with both mild and severe encephalopathy had normal blood pressures and blood gases at the time of study. Fixation of brain tissue was obtained by whole-body perfusion. Marked swelling of the cytoplasm, perineuronal and perivascular processes of astrocytes were noted in cortical gray, but not white, matter areas; the other cellular components of the brain had normal morphology. Capillary endothelial cells were normal, and there was no evidence of horseradish peroxidase in endothelial cell vesicles, basement membranes or the brain parenchyma, suggesting that the blood-brain barrier was impermeable to large molecules. Histologic evidence of brain edema is seen in this model, with swelling of astrocytes as the primary manifestation of the accumulation of water. Damage to astrocytes or inhibition of their function may contribute to the pathogenesis of hepatic encephalopathy in this model.
Subject(s)
Blood-Brain Barrier , Brain Edema/pathology , Brain/pathology , Liver Diseases/pathology , Animals , Brain/ultrastructure , Chemical and Drug Induced Liver Injury , Galactosamine , Male , Microscopy, Electron , RabbitsABSTRACT
Deficiencies of protein C activity and antigen were observed in eight consecutive patients with splanchnic venous thrombosis. There was a significant reduction in the ratio of protein C to factor X. Six of the eight patients had a decrease in antithrombin III, but free protein S antigen was within normal limits in all but two subjects. It is proposed that a thrombogenic stimulus such as stasis, altered hormonal milieu, or failure of hepatic clearance of activated coagulants results in consumption of protein C and antithrombin III, predisposing to splanchnic venous occlusion. This further impairs hepatic function, prevents restitution of protein C and antithrombin levels, and promotes continuing venous thrombosis. Thus, a vicious cycle of thrombosis and hepatic damage is perpetuated.
Subject(s)
Mesenteric Vascular Occlusion/blood , Protein C Deficiency , Thrombosis/blood , Adult , Aged , Antithrombin III/analysis , Factor X/analysis , Female , Glycoproteins/analysis , Humans , Male , Mesenteric Veins , Middle Aged , Protein SABSTRACT
Brain edema and intracranial hypertension are major complications of fulminant hepatic failure. We investigated the development of brain edema and monitored intracranial pressure in rabbits with toxic hepatitis induced by galactosamine. Using a gravimetric technique to assay small tissue samples, we found that brain water was increased in cortical grey matter, but not in subcortical, mesencephalic, and pontine white matter, or in the cerebellum. The proportion of water in cerebral grey matter in control animals was 80.96% +/- 0.49% with significant elevations to 81.96% +/- 0.47% and 82.95% +/- 1.49% in mild and severe encephalopathy, respectively. This corresponds to mean increases in tissue volume of 5.5% and 11.7%. The hippocampal grey matter also accumulated water in severe encephalopathy with a 30% increase in mean tissue volume. The regional increase in brain water was confirmed by the wet-dry weight method. Neither hypotension, hypoxia, nor severe hypoglycemia were present to account for the edema. Intracranial pressure was monitored continuously in unanesthetized rabbits via an intraventricular cannula as encephalopathy developed. The pressure was normal in the mild stage, but was intermittently elevated in animals with severe encephalopathy. The normal range of intracranial pressure was 2-9 mmHg and the range of peak values in galactosamine-treated rabbits was 18-55 mmHg. The regional differences in brain water accumulation suggest that cellular swelling and abnormalities in the movement of water across the blood-brain barrier may account for the brain edema in this model.